AIM 100

Pricing Availability   Qty
Description: Potent and selective Ack1 (TNK2) inhibitor
Chemical Name: 5,6-Diphenyl-N-[[(2S)-tetrahydro-2-furanyl]methyl]furo[2,3-d]pyrimidin-4-amine
Purity: ≥98% (HPLC)
Citations (2)
Reviews (1)
Literature (3)

Biological Activity for AIM 100

AIM 100 is a potent Ack1 (TNK2) inhibitor (IC50 = 22 nM). Exhibits selectivity for Ack1 over ABL1, BTK, Lck and LYN; exhibits no inhibition of 25 other kinases. Suppresses phosphorylation of Tyr267 of the androgen receptor in prostate cancer cells. Also suppresses growth of radioresistant castration-resistant prostate cancer in xenograft tumors in mice. Also promotes DAT endocytosis and oligomerization.

Compound Libraries for AIM 100

AIM 100 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Kinase Inhibitor Library. Find out more about compound libraries available from Tocris.

Technical Data for AIM 100

M. Wt 371.43
Formula C23H21N3O2
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 873305-35-2
PubChem ID 11501591
Smiles C1(C(C4=CC=CC=C4)=C(C5=CC=CC=C5)O3)=C3N=CN=C1NC[C@H]2OCCC2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for AIM 100

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 37.14 100
ethanol 37.14 100

Preparing Stock Solutions for AIM 100

The following data is based on the product molecular weight 371.43. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.69 mL 13.46 mL 26.92 mL
5 mM 0.54 mL 2.69 mL 5.38 mL
10 mM 0.27 mL 1.35 mL 2.69 mL
50 mM 0.05 mL 0.27 mL 0.54 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for AIM 100

Certificate of Analysis / Product Datasheet
Select another batch:

References for AIM 100

References are publications that support the biological activity of the product.

Mahajan et al (2012) Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J.Biol.Chem. 287 22112 PMID: 22566699

Mahajan et al (2010) Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate 70 1274 PMID: 20623637

Sorkina et al (2018) Small molecule induced oligomerization, clustering and clathrin-independent endocytosis of the dopamine transporter. Elife. 7 PMID: 29630493

If you know of a relevant reference for AIM 100, please let us know.

View Related Products by Product Action

View all Ack1 Inhibitors

Keywords: AIM 100, AIM 100 supplier, AIM100, ack1, inhibitors, inhibits, selective, kinases, TNK2, tyrosine, kinase, non-receptor, Androgen, Receptor, Ack1, Dopamine, Transporters, 4946, Tocris Bioscience

2 Citations for AIM 100

Citations are publications that use Tocris products. Selected citations for AIM 100 include:

Verduzco et al (2018) Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. Mol Cancer Ther 17 73 PMID: 29133622

Guy A et al (2022) Systemic RNA Interference Defective (SID) genes modulate dopaminergic neurodegeneration in C. elegans. PLoS Genet 18 e1010115 PMID: 35984862

Do you know of a great paper that uses AIM 100 from Tocris? Please let us know.

Reviews for AIM 100

Average Rating: 5 (Based on 1 Review.)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used AIM 100?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Inhibition of MEK and ACK1 suppresses long-term growth of WM209 and SK-MEL-23 cells..
By Anonymous on 11/09/2019
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: WM209 and SK-MEL-23 cells

Combined pharmacological inhibition of MEK and ACK1 suppresses long-term growth of WM209 and SK-MEL-23 cells.

PMID: 29133622
review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.